Capricor Therapeutics is trading 5.09% lower at $6.53 amid biotech and broader-market weakness; no company-specific announcement explaining the decline was identified. - XBI was down 2.01%; broader markets also fell amid hotter-than-expected inflation and rate concerns. - Capricor’s latest listed HOPE-3 data release was dated October 5, and an October 14 market summary reported no new catalyst.